FDA Blocks Imports From Another Ranbaxy Drug Plant

Law360, New York (September 16, 2013, 6:15 PM EDT) -- The U.S. Food and Drug Administration on Friday forbade the importation of drugs from a Ranbaxy Laboratories Inc. plant in India after investigators uncovered rampant violations of U.S.-promulgated manufacturing standards, another in a string of embarrassments for India’s foremost generic pharmaceutical outfit.

The FDA authorized U.S. customs officials to seize “any and all products” that originated from Ranbaxy’s manufacturing plant in Mohali, India, after determining the plant was not in compliance with a 2012 agreement holding the company to tough standards for manufacturing practices meant to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.